ERBB2 and breast cancer: One of the mechanisms of resistance to HER2 therapy involves aberrant activation of PI3K/mTOR pathway that has been implicated in the pathogenesis of BC as well as in the resistance to HER2 targeted therapies (Berns et al., 2007; O’Brien et al., 2010; Liu et al., 2017).